Drugs Made In America Acquisition II Corp. Unit logo

Drugs Made In America Acquisition II Corp. Unit (DMIIU)

Market Closed
11 Jun, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
10. 12
+0.01
+0.0989%
Pre Market
$
11. 63
+1.51 +14.9209%
706.22M Market Cap
- Div Yield
3,598 Volume
$ 10.11
Previous Close
Investors:
Add Transaction
Day Range
10.11 10.12
Year Range
9.94 10.8
Want to track DMIIU and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

DMIIU closed today higher at $10.12, an increase of 0.0989% from yesterday's close, completing a monthly decrease of -0.3447% or -$0.04. Over the past 12 months, DMIIU stock gained 1.2%.
DMIIU is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.

DMIIU Chart

Drugs Made In America Acquisition II Corp. Unit Investors

Name Quantity Cost Value Profit ($) Gain (%)
BO
Brian Oliveira Clear Street Group Inc.
236,432 $2.35M $2.4M $48,468.82 2.06%

Drugs Made In America Acquisition II Corp. Unit (DMIIU) FAQ

What is the stock price today?

The current price is $10.12.

On which exchange is it traded?

Drugs Made In America Acquisition II Corp. Unit is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is DMIIU.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 706.22M.

Has Drugs Made In America Acquisition II Corp. Unit ever had a stock split?

No, there has never been a stock split.

Drugs Made In America Acquisition II Corp. Unit Profile

NASDAQ (NMS) Exchange
US Country

Overview

Drugs Made In America Acquisition II Corp. is a newly established entity incorporated in 2024. Based in Fort Lauderdale, Florida, the company currently lacks significant operations. Its primary objective is to execute strategic business combinations, including mergers, asset acquisitions, share exchanges, recapitalizations, and reorganizations. The intent behind such activities is to partner with or acquire one or more businesses, ultimately facilitating expansion and growth within specific sectors. This approach is particularly relevant in the pharmaceutical and healthcare industries, which align with the company's name and the potential market it aims to navigate.

Products and Services

  • Business Combinations

    The company plans to engage in various forms of business combinations, enhancing its portfolio and market presence through strategic alliances and partnerships. This approach allows the firm to leverage the expertise of existing businesses in the pharmaceutical industry.

  • Mergers and Acquisitions

    Drugs Made In America Acquisition II Corp. aims to identify potential merger or acquisition targets that align with its strategic goals. By consolidating resources and capabilities, the company seeks to create synergies that can drive growth and innovation.

  • Reorganizations

    Reorganizing existing companies may be part of the company's strategy to improve operational efficiency and align business objectives. Such reorganizations can involve restructuring the management or operational frameworks of acquired entities to enhance performance.

  • Asset Acquisition

    The company intends to explore opportunities for acquiring assets from distressed or strategically aligned businesses. This could comprise tangible assets, intellectual property, or proprietary technologies that would benefit its future endeavors.

  • Recapitalization

    Through recapitalization, the company may restructure its financial assets and liabilities, optimizing its capital structure to support growth and operational sustainability. This process could involve raising funds to enhance business capabilities further.

Contact Information

Address: 1 East Broward Boulevard
Phone: 954 870 3099